{"id":"du-176b-tablets","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL5863498","moleculeType":null,"molecularWeight":"535.61"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By increasing serotonin levels, DU-176b tablets help to improve mood, reduce anxiety, and alleviate symptoms of depression. SSRIs like DU-176b tablets are commonly used to treat major depressive disorder, generalized anxiety disorder, and other conditions.","oneSentence":"DU-176b tablets are a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:35:39.177Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"}]},"trialDetails":[{"nctId":"NCT03395639","phase":"PHASE3","title":"Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2018-05-15","conditions":"Cardiac Disease","enrollment":168},{"nctId":"NCT02072434","phase":"PHASE3","title":"Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2014-03-25","conditions":"Atrial Fibrillation","enrollment":2199},{"nctId":"NCT02073682","phase":"PHASE3","title":"Cancer Venous Thromboembolism (VTE)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2015-07-16","conditions":"Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)","enrollment":1046},{"nctId":"NCT01181102","phase":"PHASE3","title":"A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2009-03","conditions":"Venous Thromboembolism","enrollment":716},{"nctId":"NCT00781391","phase":"PHASE3","title":"Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2008-11","conditions":"Stroke, Atrial Fibrillation, Embolism","enrollment":21105},{"nctId":"NCT01181141","phase":"PHASE3","title":"Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2008-10","conditions":"Venous Thromboembolism","enrollment":92},{"nctId":"NCT01181167","phase":"PHASE3","title":"A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2009-05","conditions":"Prevention, Venous Thromboembolism","enrollment":610},{"nctId":"NCT00986154","phase":"PHASE3","title":"Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2009-10","conditions":"Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)","enrollment":8292},{"nctId":"NCT01662908","phase":"PHASE2","title":"A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2012-08","conditions":"Deep Vein Thrombosis, Venous Thrombosis","enrollment":85},{"nctId":"NCT00504556","phase":"PHASE2","title":"A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2007-06","conditions":"Atrial Fibrillation, Thromboembolism","enrollment":1146},{"nctId":"NCT00806624","phase":"PHASE2","title":"DU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2007-10","conditions":"Atrial Fibrillation, Stroke","enrollment":234},{"nctId":"NCT01203072","phase":"PHASE2","title":"A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2006-07","conditions":"Venous Thromboembolism, Deep Vein Thrombosis, Total Knee Arthroplasty","enrollment":523},{"nctId":"NCT00829933","phase":"PHASE2","title":"Late Phase 2 Study of DU-176b in Patients With Non-Valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2007-03","conditions":"Atrial Fibrillation","enrollment":536},{"nctId":"NCT01203098","phase":"PHASE2","title":"A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2008-07","conditions":"Venous Thromboembolism, Thromboembolism, Thrombosis","enrollment":264},{"nctId":"NCT02221102","phase":"PHASE2, PHASE3","title":"Edoxaban for TIA and Acute Minor Stroke","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2013-12","conditions":"Ischemia, Stroke, Cerebral Infarction","enrollment":3700}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"DU-176b tablets","genericName":"DU-176b tablets","companyName":"Daiichi Sankyo Co., Ltd.","companyId":"daiichi-sankyo-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DU-176b tablets are a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain. Used for Major depressive disorder, Generalized anxiety disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}